Sequel to ‘Have a Good Trip’ Goes into Production

Good Trip Studios has announced that it has begun producing a sequel to the documentary “Have a Good Trip: Adventures in Psychedelics.” The 2020 documentary was written and directed by Emmy-winning writer, director and producer Donick Cary and hosted by Nick Offerman. The film, which included a cast of more than 30 celebrities sharing anecdotes about their experiences with hallucinogenic drugs, was released on Netflix in May 2020.

Comedy writer Donick Cary says he was inspired to write “Have a Good Trip” after talking about hallucinogenics and people’s experiences while under the influence with Fisher Stevens and Ben Stiller at the Nantucket film festival some 10 years ago.

The conversation was so entertaining that he decided to expand the “extended dinner party” format with different people sharing stories into a documentary. Over a 10-year period, Cary interviewed around 75–100 stars about their psychedelic experiences, often having to work around their filming schedules. While Cary talked about the possible therapeutic benefits of using psychedelics, he also stressed proper research and exercising caution.

Titled “Having a Good Trip 2: Adventures in Psychedelics,” the sequel will also discuss the state of psychedelics in modern society and their therapeutic potential against various mental health disorders. Like the first documentary, it will feature celebrities and comedians retelling and re-enacting their past psychedelic experiences interspersed with safety and harm-reduction methods from top psychedelic experts.

Psychedelic use has been popular within a small segment of the American population for decades despite hallucinogenic drugs being outlawed since the 1970s. In recent years, however, more permissive drug policies in countries such as the United States, Canada and Australia have led to a surge in psychedelic research that some call the psychedelic renaissance.

These studies have found that psychedelics such as psilocybin, ketamine and MDMA have the potential to treat mental health conditions, including depression, anxiety and post-traumatic stress disorder (PTSD). Psychedelic therapy seems even more effective when paired with talk therapy, producing long-term health benefits with minimal side effects on the user.

The first documentary and its sequel are only two of many pieces of media discussing psychedelics and their potential mental health benefits.

The films feature interviews with celebrity guests such as Ben Stiller, Natasha Lyonne, Carrier Fisher, Rosie Perez, Anthony Bourdain, A$ASP Rocky, Will Forte, Sting, David Cross, Shepard Fairey, Reggy Watts, Maya Erskine, Rob Corddry, Bill Kreutzmann, Nick Kroll and more.

Mike Rosenstein produced the documentary through Sunset Rose Pictures alongside Stuart Cornfield, Jim Ziegler, Jeremy Reitz and Ben Stiller via Red Hour. Cary will direct and produce the sequel via Good Trip Studios.

Such documentaries do an effective job of raising awareness about some of the work that industry actors such as Seelos Therapeutics Inc. (NASDAQ: SEEL) are doing to advance the field of psychedelics.

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.